Arbutus reacquires greater china rights to imdusiran and announces scientific advisory board with late-stage clinical focus

Qilu pharmaceutical and arbutus mutually agree to conclude strategic partnership for imdusiran in greater china

ABUS Ratings Summary

ABUS Quant Ranking